Parabilis Medicines, Inc. (PBLS)
NASDAQ · Manufacturing · Pharmaceutical preparations
$31.20−$1.27 (−3.91%) on the dayAs of the close; data may be delayed.
PBLS price, last 12 months
Key stats
- Previous close
- $32.47
- Open
- $32.53
- Day range
- $29.57 – $32.53
- 52-week range
- $24.51 – $42.49
- Volume
- 1M
- Avg volume (20 days)
- 1.1M
- Market cap
- $3.9B
Performance
1W−25.2%
1M−20.5%
3M+8.3%
6M—
YTD—
1Y—
Technicals and fundamentals
About Parabilis Medicines, Inc.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $3.9B